Abstract
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis. Given the encouraging efficacy and acceptable safety profile of daratumumab demonstrated in clinical trials, daratumumab has emerged as a novel treatment option for myeloma and became the first monoclonal antibody approved by the FDA for the treatment of MM.
Original language | English (US) |
---|---|
Article number | 51 |
Journal | Journal of Hematology and Oncology |
Volume | 9 |
Issue number | 1 |
DOIs | |
State | Published - Jun 30 2016 |
ASJC Scopus subject areas
- Molecular Biology
- Hematology
- Oncology
- Cancer Research